A randomized Phase II study of vemurafenib plus cobimetinib continuous versus intermittent, in previously untreated BRAFV600- mutation positive patients with unresectable locally advanced or metastatic melanoma.
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 21 Feb 2018
At a glance
- Drugs Cobimetinib (Primary) ; Vemurafenib (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- 14 Feb 2018 Planned End Date changed from 1 Dec 2018 to 1 Sep 2019.
- 14 Feb 2018 Planned primary completion date changed from 1 Dec 2018 to 1 Sep 2019.
- 14 Feb 2018 Status changed from recruiting to active, no longer recruiting.